The future of acute care and prevention in headache

Neurological Sciences

Volumn 28, Issue SUPPL. 2, 2007, Pages

  Krymchantowski, A V ^a,b,c   Rapoport, A M ^d   Jevoux, C C ^e  

^a Instituto de Neurologia Deolindo Couto ^*  (Brazil)

^b Instituto de Neurologia Deolindo Couto   (Brazil)

^c Headache Center of Rio de Janeiro   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Acute and preventive treatment; Cluster headache; Emerging drugs; Migraine

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BOTULINUM TOXIN A; CARVEDILOL; CIS CAPSAICIN; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIHYDROERGOTAMINE; ERGOTAMINE; ETIRACETAM; FROVATRIPTAN; NARCOTIC ANALGESIC AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OLCEGEPANT; PARACETAMOL; PETASITES HYBRIDUS EXTRACT; PLACEBO; QUETIAPINE; RIZATRIPTAN; TIAGABINE; TIZANIDINE; TOPIRAMATE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VERAPAMIL; ZONISAMIDE;

ABDOMINAL PAIN; ADD ON THERAPY; AGITATION; AMNESIA; ANALGESIC ACTIVITY; ANHIDROSIS; ANOREXIA; ANXIETY; APHASIA; ASTHENIA; ATAXIA; BURNING SENSATION; CARCINOGENICITY; CHRONIC DAILY HEADACHE; CLINICAL TRIAL; CLUSTER HEADACHE; COMMON COLD; CONCENTRATION LOSS; CONFUSION; DECREASED APPETITE; DELUSION; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; ECONOMIC ASPECT; ENZYME INHIBITION; ERUCTATION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; INJECTION SITE REACTION; INSOMNIA; INTRAOCULAR HYPERTENSION; LACRIMATION; LETHARGY; LEUKOPENIA; LOW DRUG DOSE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATIENT COMPLIANCE; PRIMARY PREVENTION; PTOSIS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOCIAL ASPECT; SOMNOLENCE; SYSTEMIC DISEASE; TASTE DISORDER; THOUGHT DISORDER; TRANSFORMED MIGRAINE; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIOLENCE; VISUAL IMPAIRMENT; WEAKNESS; WEIGHT REDUCTION;

ANALGESICS; BRAIN CHEMISTRY; DRUG DESIGN; HUMANS; ION CHANNELS; MIGRAINE DISORDERS; NEUROLOGY; NEUROPHARMACOLOGY; NEUROTRANSMITTER AGENTS; PSYCHOTROPIC DRUGS;

EID: 34249297068     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-007-0772-6     Document Type: Review

References (93)

1. Stewart WF, Shechter A, Lipton RB (1994) Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Neurology 44[Suppl 14]:S24-S39
2. Goadsby PJ (2001) Pathophysiology of migraine. In: Silberstein SD, Lipton RB, Dalessaio DJ (eds) Wolff's headache and other head pain, 7th edn. Oxford University Press, Oxford, pp 57-72
3. May A, Goadsby PJ (1999) The trigeminovascular system in humans: pathophysiology implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 19:115-127
4. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine - current understanding and treatment. N Engl J Med 346:257-270
5. Welch KMA, Barkley GL, Tepley N et al (1993) Central neurogenic mechanisms of migraine. Neurology 43:S21-S25
6. Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol 55:19-26
7. Tfelt-Hansen P, Block G, Dahlöf C et al (2000) Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia 20:765-786
8. Silberstein SD (2000) Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology 55:754-763
9. Dodick DW (2001) Acute and prophylactic management of migraine. Clin Cornerstone 4:36-52
10. Sheftell FD, Feleppa M, Tepper SJ et al (2004) Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 44:661-668
11. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 358:1668-1675
12. Ramadan MN, Silberstein SD, Freitag FG et al. Pharmacological management for prevention of migraine. http://www.aan.com/public/practiceguidelines/ (accessed July 2005)
13. Matchar DB,Young WB, Rosenerg J et al. Multispecialty consensus on diagnosis and treatment of headache: Pharmacological management of acute attacks. http://www.aan.com/public/practiceguidelines/ (accessed July 2005)
14. Bigal ME, Lipton RB, Krymchantowski AV (2004) The medical management of migraine. Am J Ther 11:130-140
15. Dodgson SJ, Shank RP, Maryanoff BE (2000) Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41:35-39
16. Sigel E (1995) Functional modulation of ligand-gated GABAA and NMDA receptor channels by phosphorylation. J Receptor Signal Transduct Res 15:325-332
17. Gibbs JW, Sombati S, Delorenzo RJ, Coulter DA (2000) Cellular actions of topiramate: Blockade of kainite-evoked inward currents in cultured hippocampal neurons. Epilepsia 41[Suppl 1]:S10-S16
18. Shuaib A, Ahmed F, Muratoglu M, Kochanski P (1999) Topiramate in migraine prophylaxis: A pilot study. Cephalalgia 19:379-380
19. Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group (2004) Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 61:490-495
20. Brandes JL, Saper JR, Diamond M et al; MIGR-002 Study Group (2004) Topiramate for migraine prevention: A randomized controlled trial. JAMA 291:965-973
21. Campistol J, Campos J, Casas C, Herranz JL (2005) Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 20:251-253
22. Pelloch JM, Willmore LJ (1991) A rational guide to routine blood monitoring in patients receiving anti-epileptic drugs. Neurology 41:961-964
23. Drake Jr ME, Kay AM, Knapp MS, Greathouse NI (1999) An open-label trial of tiagabine for migraine prophylaxis. Headache 39:352
24. Freitag FG, Diamond S, Diamond ML et al (1999) The prophylaxis of migraine with the GABA-agonist, tiagabine: A clinical report. Headache 39:354
25. Klitgaard H, Matagne A, Gobert J,Wulfert E (1998) Evidence for a unique profile of levetiracetam in rodent model of seizures and epilepsy. Eur J Pharmacol 353:191
26. Nicolas JM, Collart P, Gerin B et al (1999) In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 27:250-254
27. Drake ME, Greathouse NI, Armentbright AD, Renner JB (2001) Levetiracetam for preventive treatment of migraine. Cephalalgia 21:373
28. Krusz JC (2001) Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 21:373
29. Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME (2005) Levetiracetam in the preventive treatment of transformed migraine. Curr Ther Res 66:212-221
30. Vaisleb I, Neft R, Schor N (2005) Role of Levetiracetam in prophylaxis of migraine headaches in childhood. Neurology 64[Suppl 1]:A343
31. Schmidt D, Jacob R, Loiseau P et al (1993) Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial. Epilepsy Res 15:67-73
32. Ito T, Hori M, Kadokawa T (1985) Effects of zonizamide (AD-810) on tungistic acid gel-induce thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharge in cats. Epilepsia 27:367-374
33. Yagi K, Seino M (1992) Methodological requirements for clinical trials in refractory epilepsies: Our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 16:79-85
34. Mimaki T (1998) Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 20:593-597
35. Krusz JC (2001) Zonisamide in the treatment of headache disorders. Cephalalgia 21:374-375
36. Drake ME, Greathouse NI, Armentbright AD, Renner JB (2001) Preventive treatment of migraine with zonisamide. Cephalalgia 21:374
37. Eaton J (1998) Butterbur, herbal help for migraine. Nat Pharm 2:23-24
38. Lin H, Chien CH, Lin YL et al (2000) Inhibition of testosterone secretion by S-petasin in rat testicular interstitial cells. Chin J Physiol 43:99-103
39. Grossmann M, Schmidramsl H (2000) An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 38:430-435
40. Lipton RB, Gobel H,Wilks K, Mauskop A (2002) Efficacy of petasites (an Extract from Petasites Rhizone) 50 and 75 mg for prophylaxis of migraine: Results of a randomized, doubleblind, placebo controlled study (abstract). Neurology 58:A472
41. Cleophus TJ, Zwinderman AH (2001) Beta-blockers and heart failure: meta-analysis of mortality trials. Int J Clin Pharm Ther 39:383-387
42. Kaniecki RG (2003) Migraine prevention with Carvedilol: A prospective, open-label trial. Headache 43:589
43. Zaimis E, Hanington E (1969) A possible pharmacological approach to migraine. Lancet 2:298-300
44. D'Andrea G, Perini F, Granella F et al (1997) Efficacy of transdermal clonidine in the treatment of cluster headache. In: Olesen J, Tfelt-Hansen P (eds) Headache treatment. Trial methodology and new drugs. Lippincott-Raven, Philadelphia, pp 335-340
45. Saper JR, Lake AE, Cantrell DT et al (2002) Chronic daily headache prophylaxis with tizanidine: A double blind, placebo controlled, multicenter outcome study. Headache 42:470-482
46. Krusz JC, Belanger J, Mills C (2000) Tizanidine: A novel effective agent for the treatment of chronic headaches. Headache 11:41-45
47. Seeman P, Tallerico T (1999) Rapid release of antipsychotic drugs from Dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine and quetiapine. Am J Psychiatry 156:876-884
48. Schatzberg AF, Cole JO, Debattista C (2002) Manual of clinical psychopharmacology, 4th edn. American Psychiatric Publishing, Washington, pp 199-200
49. Brandes JL, Roberson SC, Pearlman SH (2002) Quetiapine for migraine prophylaxis. Headache 42:450-451
50. Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35-42
51. Volknandt W (1995) Commentary: The synaptic vesicle and its targets. Neuroscience 64:277-300
52. Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW (2002) Treatment of headache with botulinum toxin A - a review according to evidence-based medicine criteria. Cephalalgia 22:699-710
53. Silberstein SD, Mathew NT, Saper J, Jenkins S, for the Botox Migraine Clinical Research Group (2000) Botulinum toxin type A as a migraine preventive treatment. Headache 40:445-450
54. Ondo W, Vuong K, Derman H (2004) Botulinum toxin A for chronic daily headache: A randomized, placebo-controlled, parallel-design study. Cephalalgia 24:60-65
55. Humphrey PPA, Goadsby PJ (1994) Controversies in headache. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 14:401-410
56. Maassen Vandenbrink A, Reekers M, Bax WA et al (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98:25-30
57. Buchanan TM, Ramadan NM, Aurora S (2004) Future pharmacologic targets for acute and preventive treatments of migraine. Expert Rev Neurotherapeutics 4:391-430
58. McCall RB, Huff R, Chio CL et al (2002) Preclinical studies characterizing the antimigraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633. Cephalalgia 22:799-806
59. Fleishaker JC, Pearson LK, Knuth DW et al (1999) Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633. Int J Clin Pharmacol Ther 37:487-492
60. Gomez-Mancilla B, Cutker NR, Leibowitz MT et al (2001) Safety and tolerability of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 21:727-732
61. Adham N, Kao HT, Schecter LE et al (1993) Cloning of another human serotonin receptor (5-HT1F): A fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 90:408-412
62. Shepheard S, Edvinsson L, Cumberbatch M et al (1999) Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 19:851-858
63. Phebus LA, Johnson KW, Zgombick JM et al (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61:2117-2126
64. Goldstein DJ, Roon KI, Offen WW et al (2001) Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: A randomised controlled trial. Lancet 358:1230-1234
65. Reeve AJ, Dickenson AH (1995) The roles of spine adenosine receptors in the control of acute and more persistent nociceptive responses of dorsal horn neurons in the anesthetized rats. Br J Pharmacol 116:2221-2228
66. Schindler M, Harris CA, Hayes B et al (2001) Immunohistochemical localization of adenosine A1 receptors in human brain regions. Neurosci Lett 297:211-215
67. Gurden MF, Coates J, Ellis F et al (1993) Functional characterization of three adenosine receptor subtypes. Br J Pharmacol 109:693-698
68. Bland-Ward PA, Fentiuk W, Humphrey PPA (2000) The adenosine A1 receptor agonist GR79236 inhibits evoked fir- ing of trigeminal nucleus caudalis (TNC) neurons in the rat. Cephalalgia 20:271-274
69. Goadsby PJ, Hoskin KL, Storer RJ et al (2002) Adenosine (A1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 125:1392-1401
70. Giffin NJ, Kowacs F, Libri V et al (2003) Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy humans subjects. Cephalalgia 23:287-292
71. Hou M, Uddman R, Tajti J et al (2002) Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci Lett 330:223-226
72. Markowitz S, Saito K, Moskowitz M (1987) Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. Neurosci 7:4129-4136
73. Diamond S, Freitag F, Phillips S et al (2000) Intranasal civamide for the acute treatment of migraine headache. Cephalalgia 20:597-602
74. Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L (2003) In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 481:207-216
75. Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23:193-196
76. Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43[Suppl 3]:S16-S20
77. Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183-187
78. Doods H, Hallermayer G,Wu D et al (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420-423
79. Iovino M, Feifel U,Young CL et al (2004) Safety, tolerability and pharmacokinetics of BIBN4096BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 24:645-656
80. Olesen J, Diener HC, Husstedt IW et al (2004) BIBN4096BS Clinical Proof of Concept Study. Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine. N Engl J Med 350:1104-1110
81. Bereiter DA, Benetti AP (1996) Excitatory amino acid release within spinal trigeminal nucleus after mustard oil injection into the temporomandibular joint region of the rat. Pain 67:451-459
82. Fundytus ME (2001) Glutamate receptors and nociception: Implications for the drug treatment of pain. CNS Drugs 15:29-58
83. Nelson KA, Park KM, Robinovitz E et al (1997) High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 48:1212-1218
84. Sang CN, Hostetter MP, Gracely RH et al (1998) AMPA/kainite antagonist LY-293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 89:1060-1067
85. Sang CN, Ramadan NM, Wallihan RG et al (2004) LY293558, a novel AMPA/ GluR5 antagonist, is efficacious and web-tolerated in acute migraine. Cephalalgia 24:596-602
86. Tassorelli C, Joseph SA, Buzzi MG, Nappi G (1999) The effects on central nervous system of nitroglycerine - putative mechanism and mediators. Prog Neurobiol 57:607-624
87. Read SJ, Smith MI, Hunter AJ, Parsons AA (1997) Enhanced nitric oxide release during cortical spreading depression following infusion of glyceryl trinitrate in the anesthetized cat. Cephalalgia 17:159-165
88. Olesen J, Iversen HK, Thomsen LL (1993) Nitric oxide supersensitivity. A possible molecular mechanism of migraine pain. Neuroreport 4:1027-1030
89. Lassen LH, Ashina M, Christiansen I et al (1998) Nitric oxide synthase inhibition: A new principle in the treatment of migraine attacks. Cephalalgia 18:27-32
90. Lassen LH, Christiansen I, Iversen HK et al (2003) The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 23:877-886
91. Ashina A, Lassen LH, Bendtsen L et al (1999) Effect of inhibition of nitric oxide synthase on chronic tension-type headache: A randomised crossover trial. Lancet 353:287-289
92. Leone M, Franzini A, Broggi G, Bussone G (2006) Hypothalamic stimulation for intractable cluster headache: Long-term experience. Neurology 67:150-152
93. Leone M, Franzini A, Broggi G et al (2006) Acute hypothalamic stimulation and ongoing cluster headache attacks. Neurology 67:1844-1845